Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease

Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease

The role of gut microbiota (GM) in the pathogenesis of Symptomatic Uncomplicated Diverticular Disease (SUDD) remains controversial. Here, we assessed the efficacy of a butyrate formulation in modulating GM and abdominal pain in patients with SUDD. A retrospective study was conducted in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Antonio Tursi, Giorgia Procaccianti, Rudi De Bastiani, Silvia Turroni, Federica D’Amico, Leonardo Allegretta, Natale Antonino, Elisabetta Baldi, Carlo Casamassima, Giovanni Casella, Mario Ciuffi, Marco De Bastiani, Lorenzo Lazzarotto, Claudio Licci, Maurizio Mancuso, Antonio Penna, Giuseppe Pranzo, Guido Sanna, Cesare Tosetti, Maria Zamparella, Marcello Picchio
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Medicine
Subjects:
diverticulosis
symptomatic uncomplicated diverticular disease
gut microbiota
primary care
abdominal pain
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1487892/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of gut microbiota (GM) in the pathogenesis of Symptomatic Uncomplicated Diverticular Disease (SUDD) remains controversial. Here, we assessed the efficacy of a butyrate formulation in modulating GM and abdominal pain in patients with SUDD. A retrospective study was conducted in patients with SUDD who were treated with a delayed- and colonic-release formulation of butyrate (two capsules bid, for a total dose of 400 mg butyrate) for 3 months. GM was profiled before (T0) and after 90 days of treatment (T2) using 16S rRNA amplicon sequencing. The primary endpoint was change in GM at T2; secondary endpoints were reduction in abdominal pain severity according to VAS (Visual Analog Scale, 0: absence; 10: maximum severity) at T1 (45 days) and T2, stool characteristics according to the Bristol stool form scale at T0, T1 and T2, and safety of treatment. Fifty-nine patients with SUDD (59.3% male; median age 65.5 years, interquartile range 55–71 years) completed treatment. The butyrate formulation increased GM diversity and resulted in several compositional changes that were closely related to baseline abdominal pain severity. Regarding secondary endpoints, abdominal pain decreased significantly over time, while the Bristol stool form scale did not. Mild adverse events were recorded in 3 (5.08%) patients. This study showed that a microencapsulated and colonic-release formulation of butyrate favorably modulates GM and reduces abdominal pain in patients with SUDD.
ISSN:2296-858X

Similar Items